Genmab — Juni 2022
-
Seagan menes at være $40bn værd i et M&A scanarie jf denne analytiker https://endpts.com/in-lieu-of-hard-ma-news-one-group-of-analysts-crunches-the-numbers-around-a-40b-seagen-buy/
-
Video - A Promising Future for Treating Multiple Myeloma with Bispecific Antibodies https://www.proinvestor.com/boards/104195
-
Meget begejstrede forskerkommentarer om de bispecifikkei i videoen til slut ( fra 56-57 min) .
-
God morgen.
-
En stor tak til alle jer som tålmodigt bidrager med stort og småt/seriøst og sjovt i debat og chats, https://www.proinvestor.com/boards/104204/
-
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta
(ofatumumab) had no evidence of disease activity (NEDA-3) https://www.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3 -
Transactions in connection with share buy-back program https://ir.genmab.com/news-releases/news-release-details/transactions-connection-share-buy-back-program-17
-
Thanks E L.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind